Krishnan K Mahadevan
5PUBLICATIONS
54CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Sep 03, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Kathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker
|Aug 12, 2025
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinoma.Kathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li
|Mar 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients.Valerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan
|Jun 27, 2024
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer.Krishnan K Mahadevan, Allison M Dyevoich, Yang Chen
|Feb 24, 2023
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent manner.Krishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu
Pageof 1
Frequent Collaborators
5 joint publications
Raghu Kalluri
4 joint publications
Kathleen M McAndrews
3 joint publications
Paola A Guerrero
3 joint publications
Anirban Maitra
3 joint publications
Amari M Sockwell
2 joint publications
Valerie S LeBleu
2 joint publications
Hikaru Sugimoto
2 joint publications
Lakshmi Kavitha Sthanam
2 joint publications
Bingrui Li
1 joint publications
Timothy P Heffernan
